| abstract |
Disclosed are 3-sulphonyl-2-oxo-chromene derivatives as represented by the general formula (I), wherein Q is O; R2 is a substituted or unsubstituted aryl or heteroaryl (as defined herein); and wherein the 2-oxo-chromene moiety is substituted with at least one substituent R1; and wherein the remaining substituents are as defined herein. Also disclosed is a pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a compound as defined above for the treatment of a range of proliferative disorders and conditions such as hemangiomatosis in a newborn, secondary progressive multiple sclerosis, chronic progressive myelodegenerative disease, neurofibromatosis, keloid formation, Paget's disease of the bone, fibrocystic disease of the breast, uterine fibroids, Peyronie's fibrosis, Dupuytren's fibrosis, restenosis, benign proliferative breast disease, benign prostatic hyperplasia, X-linked lymphoproliferative disorder, post-transplantation lymphoproliferative disorder, macular degeneration, retinopathies, and non-cancerous lymphoproliferative disorders. |